Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Immuron Limited ( (AU:IMC) ) has issued an update.
Immuron Limited has announced a new research collaboration with Monash University aimed at tackling antimicrobial resistance, a significant global healthcare challenge. The collaboration will explore developing therapeutic drug products targeting antimicrobial resistant pathways and Vancomycin-resistant enterococci (VRE), with no additional funding needed initially as it’s covered by Immuron’s existing research budget. The outcomes could lead to negotiations for joint development or commercialization, holding potential implications for healthcare systems and market demand for novel treatments in the antibiotic sector.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company focusing on the development and commercialization of orally delivered targeted polyclonal antibodies for infectious diseases. One of its primary products, Travelan®, is used to prevent traveler’s diarrhea by targeting and binding to diarrhea-causing bacteria, preventing their colonization and related symptoms.
YTD Price Performance: 2.63%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €11.47M
See more data about IMC stock on TipRanks’ Stock Analysis page.
